Gobiquity picks up Series B to advance smartphone amblyopia screening app


Gobiquity, which markets a smartphone vision screening app, reeled in $6 million in a first close of its Series B round. The funds will drive the company’s commercial growth, with a main focus on product development and global expansion.

The GoCheck Kids app is available to healthcare professionals for the early detection of conditions that can lead to amblyopia in children. Also called "lazy eye," amblyopia is the loss of vision in one eye, usually caused by the brain favoring the use of the other eye. It can lead to permanent vision loss. Catching the precursor conditions to amblyopia--such as strabismus, myopia (nearsightedness) or hyperopia (farsightedness)--is key as treatment efficacy starts to diminish at age 5, according to Gobiquity.

GoCheck Kids uses a smartphone camera and flash to analyze a child’s “red” reflex in one photo. The flash causes a reflection in the eye, which sometimes includes a crescent. The size and orientation of this crescent can help pediatricians determine what kind of refractive error the child has in his or her eye(s).


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The app launched on iOS last year and has since been used to screen more than 100,000 children. It is currently averaging more than 3,000 screenings per week, Gobiquity said in the statement. One of its goals is to make the tool available on platforms beyond iOS, CEO Andrew Burns told FierceMedicalDevices.

The main priority for this financing round is broadening the audience that has access to this tool, CEO Andrew Burns told FierceMedicalDevices. GoCheck Kids is currently available only in the U.S., and Gobiquity wants to bring the test to a broader group of health professionals and caregivers in the U.S. and overseas, Burns said. The company is working to address a treatment gap where people are simply not getting tested and treated for amblyopia and the conditions that cause it.

The second priority for the funding is additional R&D to expand the clinical applications of the tool, Burns said. The company initially targeted children aged one to 6 before including children up to age 10. In the long term, it wants to address conditions affecting adults, especially older adults.

- here's the statement

Related Articles:
Novel device tests suitability of lens implants
IBM taps Bausch + Lomb to develop new cataract surgery app
FDA approves first near vision correcting implant that doesn't require cataract surgery

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.